Alpha Teknova (NASDAQ:TKNO) Hits New 52-Week High – Still a Buy?

Alpha Teknova, Inc. (NASDAQ:TKNO) reached a new 52-week high on Tuesday . The company traded as high as $9.72 and last traded at $9.45, with a volume of 208104 shares traded. The stock had previously closed at $7.68.

Alpha Teknova Trading Up 12.0 %

The company has a market capitalization of $458.45 million, a PE ratio of -11.62 and a beta of 0.37. The company has a fifty day simple moving average of $7.28 and a 200-day simple moving average of $4.84. The company has a current ratio of 4.73, a quick ratio of 3.94 and a debt-to-equity ratio of 0.12.

Alpha Teknova (NASDAQ:TKNO) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. The firm had revenue of $9.58 million during the quarter, compared to analysts’ expectations of $9.30 million. During the same period in the prior year, the company posted ($0.34) EPS. Analysts predict that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TKNO. Point72 Asset Management L.P. acquired a new stake in Alpha Teknova during the third quarter worth $1,483,000. Roubaix Capital LLC purchased a new stake in Alpha Teknova in the 3rd quarter valued at about $2,015,000. Geode Capital Management LLC raised its holdings in Alpha Teknova by 24.4% in the 3rd quarter. Geode Capital Management LLC now owns 188,173 shares of the company’s stock valued at $911,000 after buying an additional 36,914 shares during the period. Finally, State Street Corp lifted its position in Alpha Teknova by 249.3% in the third quarter. State Street Corp now owns 76,645 shares of the company’s stock valued at $371,000 after buying an additional 54,700 shares during the last quarter. 13.81% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.